GlassScriptPhysician profile
Hui-Ju Liu
NPI 1245884485
$5,025.20
in general payments reported to CMS, 2019-2025
23 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $464 · 2023: $1,496 · 2024: $1,418 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.32 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $927.68 | 2023-2025 | Vemlidy |
| Amgen INC. | $585.43 | 2021-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $440.68 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $430.48 | 2022-2024 | |
| Abbvie INC. | $400.57 | 2021-2025 | |
| Lilly USA, LLC | $392.22 | 2022-2025 | Jardiance, Emgality, Mounjaro |
| Janssen Biotech, INC. | $279.33 | 2024-2025 | Rybrevant, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $255.32 | 2024-2025 | |
| Horizon Therapeutics Plc | $183.39 | 2022-2023 | Tepezza |
| Amarin Pharma, INC. | $171.53 | 2021-2023 | |
| Novo Nordisk INC | $150.00 | 2022-2024 | Ozempic |
| Glaxosmithkline, LLC. | $132.57 | 2023-2025 | Jemperli, Zejula, Trelegy Ellipta |
| Tempus Ai, INC | $126.94 | 2024 | Xt Cdx |
| Esperion Therapeutics, INC. | $116.86 | 2023 | Nexletol, Nexlizet |
| Exact Sciences Corporation | $86.24 | 2024-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.10 | 2023-2024 | Camzyos, Sotyktu |
| Genentech USA, INC. | $64.13 | 2025 | Tecentriq |
| Merck Sharp & Dohme LLC | $60.82 | 2022-2025 | Keytruda, Vaxneuvance, Pneumovax 23 |
| Astellas Pharma US INC | $43.55 | 2023 | Veozah |
| Tersera Therapeutics LLC | $40.90 | 2025 | Zoladex |
| Kowa Pharmaceuticals America, INC. | $30.18 | 2023-2024 | Zoryve, Seglentis, Livalo |
| Nestle Healthcare Nutrition INC. | $20.03 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.25 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui-Ju Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.